629 related articles for article (PubMed ID: 27486981)
1. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
2. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.
Palomo L; Xicoy B; Garcia O; Mallo M; Ademà V; Cabezón M; Arnan M; Pomares H; José Larrayoz M; José Calasanz M; Maciejewski JP; Huang D; Shih LY; Ogawa S; Cervera J; Such E; Coll R; Grau J; Solé F; Zamora L
Am J Hematol; 2016 Feb; 91(2):185-92. PubMed ID: 26509444
[TBL] [Abstract][Full Text] [Related]
3. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
[TBL] [Abstract][Full Text] [Related]
4. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
6. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape of chronic myelomonocytic leukemia in Chinese patients.
Nie Y; Shao L; Zhang H; He CK; Li H; Zou J; Chen L; Ji H; Tan H; Lin Y; Ru K
Exp Hematol Oncol; 2022 May; 11(1):32. PubMed ID: 35610628
[TBL] [Abstract][Full Text] [Related]
8. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
[No Abstract] [Full Text] [Related]
9. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic risk stratification in chronic myelomonocytic leukemia.
Such E; Cervera J; Costa D; Solé F; Vallespí T; Luño E; Collado R; Calasanz MJ; Hernández-Rivas JM; Cigudosa JC; Nomdedeu B; Mallo M; Carbonell F; Bueno J; Ardanaz MT; Ramos F; Tormo M; Sancho-Tello R; del Cañizo C; Gómez V; Marco V; Xicoy B; Bonanad S; Pedro C; Bernal T; Sanz GF
Haematologica; 2011 Mar; 96(3):375-83. PubMed ID: 21109693
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Transplant Cell Ther; 2021 Dec; 27(12):991.e1-991.e9. PubMed ID: 34500124
[TBL] [Abstract][Full Text] [Related]
12. Age-related mutations and chronic myelomonocytic leukemia.
Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
[TBL] [Abstract][Full Text] [Related]
13. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
[TBL] [Abstract][Full Text] [Related]
14. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
15. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.
Patnaik MM; Barraco D; Lasho TL; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2017 Jan; 92(1):56-61. PubMed ID: 27733013
[TBL] [Abstract][Full Text] [Related]
16. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
17. Genomic determinants of chronic myelomonocytic leukemia.
Patel BJ; Przychodzen B; Thota S; Radivoyevitch T; Visconte V; Kuzmanovic T; Clemente M; Hirsch C; Morawski A; Souaid R; Saygin C; Nazha A; Demarest B; LaFramboise T; Sakaguchi H; Kojima S; Carraway HE; Ogawa S; Makishima H; Sekeres MA; Maciejewski JP
Leukemia; 2017 Dec; 31(12):2815-2823. PubMed ID: 28555081
[TBL] [Abstract][Full Text] [Related]
18. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
Hunter A; Padron E
Curr Hematol Malig Rep; 2021 Jun; 16(3):247-255. PubMed ID: 33660195
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
Patnaik MM; Tefferi A
Blood Cancer J; 2016 Feb; 6(2):e393. PubMed ID: 26849014
[TBL] [Abstract][Full Text] [Related]
20. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]